Medullary Thyroid Cancer - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 95 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Medullary Thyroid Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Medullary Thyroid Cancer - Pipeline Review, H1 2015', provides an overview of the Medullary Thyroid Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Medullary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Medullary Thyroid Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Medullary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Medullary Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Medullary Thyroid Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Medullary Thyroid Cancer - Overview 8
Pipeline Products for Medullary Thyroid Cancer - Comparative Analysis 9
Medullary Thyroid Cancer - Therapeutics under Development by Companies 10
Medullary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 11
Medullary Thyroid Cancer - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Medullary Thyroid Cancer - Products under Development by Companies 15
Medullary Thyroid Cancer - Products under Investigation by Universities/Institutes 16
Medullary Thyroid Cancer - Companies Involved in Therapeutics Development 17
Advenchen Laboratories, LLC 17
Ariad Pharmaceuticals, Inc. 18
AstraZeneca PLC 19
Boehringer Ingelheim GmbH 20
Globeimmune, Inc. 21
Ignyta, Inc. 22
Immunomedics, Inc. 23
Nerviano Medical Sciences S.r.l. 24
Novartis AG 25
Medullary Thyroid Cancer - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by 31
Assessment by Molecule Type 33
Drug Profiles 35
AL-3818 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CLM-29 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
everolimus - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
GI-6207 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
nintedanib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NMS-616 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
pasireotide - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ponatinib hydrochloride - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
RXDX-104 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule to Inhibit RET for Medullary Thyroid Cancer - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
TF-2 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
vandetanib - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Medullary Thyroid Cancer - Recent Pipeline Updates 64
Medullary Thyroid Cancer - Dormant Projects 87
Medullary Thyroid Cancer - Product Development Milestones 88
Featured News & Press Releases 88
Apr 08, 2013: Ariad Pharma Presents New Preclinical Data On Ponatinib At AACR Annual Meeting 2013 88
Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer 88
Feb 21, 2012: European Commission Approves AstraZeneca's CAPRELSA For Patients With Medullary Thyroid Cancer 89
Nov 18, 2011: AstraZeneca Announces CAPRELSA Receives Positive CHMP Opinion In EU For Treating Advanced Medullary Thyroid Cancer 90
Apr 25, 2011: AstraZeneca Announces Vandetanib Now Available To US Patients With Advanced Medullary Thyroid Cancer 90
Apr 25, 2011: AstraZeneca Selects Biologics As Exclusive Channel Partner for Vandetanib 90
Jan 07, 2011: AstraZeneca Announces Extension Of Review Timeline For Vandetanib NDA From FDA 91
Dec 02, 2010: AstraZeneca Reports FDA Panel Recommendation Of Vandetanib NDA In Advanced Medullary Thyroid Cancer 91
Sep 23, 2010: AstraZeneca Reports Acceptance For Review Of Regulatory Submissions Of VANDETANIB From US And EU 92
Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 93
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 94
Disclaimer 95

List of Tables
Number of Products under Development for Medullary Thyroid Cancer, H1 2015 8
Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Medullary Thyroid Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015 17
Medullary Thyroid Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 18
Medullary Thyroid Cancer - Pipeline by AstraZeneca PLC, H1 2015 19
Medullary Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 20
Medullary Thyroid Cancer - Pipeline by Globeimmune, Inc., H1 2015 21
Medullary Thyroid Cancer - Pipeline by Ignyta, Inc., H1 2015 22
Medullary Thyroid Cancer - Pipeline by Immunomedics, Inc., H1 2015 23
Medullary Thyroid Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 24
Medullary Thyroid Cancer - Pipeline by Novartis AG, H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Medullary Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2015 64
Medullary Thyroid Cancer - Dormant Projects, H1 2015 87